Induced pluripotent stem cells are a type of pluripotent stem cell that can be created from differentiated (“adult”) cells. iPSCs are increasingly being explored for applications within drug development and discovery. This is because patient-derived somatic cells (for example, fibroblasts) can be reprogrammed to produce iPSCs that have disease-specific genetic aberrations. These cells can then be differentiated into the disease-affected cell type (for example, neurons in neurodegenerative diseases). [Read more…]
SERAXIS Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy
GERMANTOWN, Md., Nov. 12, 2018 — SERAXIS Inc., a rapidly growing regenerative medicine company today announced the publication of important trial considerations for SR-01, its pluripotent stem cell-derived islet therapy for insulin-dependent diabetes.
An analysis of islet transplant trials registered on clinicaltrials.gov was conducted with the goal of extracting insights to apply in the study design of SERAXIS lead candidate, SR-01 for the treatment of type 1 diabetes. The results of this analysis were published this week in Stem Cells Translational Medicine (doi:10.1002/sctm.18-0156). SR-01 is a combination therapy of insulin-producing cells encapsulated in the retrievable biocompatible SeraGraftTM device, designed to prevent immune system access to the cells after implantation. [Read more…]
Cynata’s “Major Breakthrough” in MSC Manufacturing – Unlimited Quantities, Uniform Batches, Single Donor, & Low Cost
For years, it has been clear that mesenchymal stem cells (MSCs) are a leading type of stem cell being investigated for therapeutic applications, as they have the potential to treat a wide range of acute and degenerative diseases. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic.
MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and appear to be immuno-privileged. Importantly, MSCs also well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues. [Read more…]
BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis
NEW YORK, Nov. 19, 2018 — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of NurOwn® in patients with progressive multiple sclerosis (MS).
“This important step toward the development of NurOwn® in progressive MS confirms our commitment to bring to the market innovative cellular therapies for neurodegenerative disease,” said Chaim Lebovits, president and CEO of BrainStorm. “This builds upon the important progress made in advancing NurOwn® in the ongoing pivotal study in ALS.” [Read more…]
The Market for Cord Blood and Tissue Banking in China
China represents a unique and compelling market for cord blood and tissue banking. First, the Chinese government only supports one cord blood bank within each of the provinces. Specifically, the Chinese government issues one cord blood banking license per province, and the licensed company must function as hybrid “public and private” bank.
The private, for-profit division of the company is expected to fund the company’s public, donation-based division, because no government support is given to support its processing and storage of donated units.
In this article:
- « Previous Page
- 1
- …
- 107
- 108
- 109
- 110
- 111
- …
- 201
- Next Page »